Cancer specialist goes for a dual listing
Saturday 03 July 2004
Cyclacel, the Scottish biotech company, yesterday became the latest healthcare group to reveal plans to float on Nasdaq and the London Stock Exchange.
The company, which specialises in pioneering cancer treatments, is planning to offer 16 million shares - about 26 per cent of the business - at an indicative price range of between 152p and 182p. This would give Cyclacel a market capitalisation of £91m.
Spiro Rombotis, the chief executive of Cyclacel, said the company was in a race to get its treatments to the market before larger pharmaceutical rivals. "We have the chance to be first to market in a massively important cancer field after Aventis unexpectedly terminated its development of a similar class of drug," Mr Rombotis said. He expects Cyclacel's lead drug, which treats a rare form of blood cancer, to reach the market as early as 2006.
"We have the opportunity to raise new funds when investors can see daylight in our plans.
"Without capital raising it would have been difficult to continue funding the pipeline and investing in the business," he said.
Mr Rombotis and the rest of the management team hold a 13 per cent stake in the business, which will be worth £14m when the company floats. The rest of the share capital is held by about 40 investors from across the globe. All existing shareholders are holding on to their holdings.
Cyclacel had considered floating in 2003, but was put off by weak equity markets and poor sentiment towards new listings. Its decision to float now follows a trend of biotech companies returning to the market.
Not all have been very successful, however. Ark Therapeutics floated in March, but the shares are trading well below its listing price. Norwood Immunology, the new vehicle for Rolf Stahel, formerly of Shire Pharmaceuticals, halved its valuation to £50m.
- 1 The political parties aren't all the same – which means 2015 will be a 'big-choice' election
- 2 President of Argentina adopts Jewish godson to 'stop him turning into a werewolf'
- 3 ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
- 4 The 'Black Museum': After 150 years, public set to see exhibits from police’s grisly crime museum
President of Argentina adopts Jewish godson to 'stop him turning into a werewolf'
Exclusive: Abusers using spyware apps to monitor partners reaches 'epidemic proportions'
ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
UK weather: Warning for more snow and ice as freezing temperatures and gales hit Britain
New York police shooting: thousands turn out for the funeral of Rafael Ramos
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Immigrants make UK racist, says Ukip councillor Trevor Shonk
Nigel Farage: Ukip leader named 'Briton of the year' by The Times
BBC director Danny Cohen: Rising UK antisemitism makes me feel more uncomfortable than ever
iJobs Money & Business
Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...
Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...
Not specified: Selby Jennings: SVP Model Validation This top tiered investment...
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...